Galectin Therapeutics Inc.
Company Snapshot: Galectin Therapeutics Inc.
Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.
- Sep 17 2019 Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy
- Aug 9 2019 Galectin Therapeutics Reports Q2 2019 Financial Results and Provides Business Update
- Aug 5 2019 Galectin Therapeutics Submits Phase 3 NASH-RX Protocol in Nash Cirrhosis to FDA
- May 28 2019 Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant Exercise